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Abstract
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate
and acquired drug resistance. In order to better understand the mechanisms underlying
acquired cisplatin resistance, we have compared the adenocarcinoma-derived non-small cell
lung cancer (NSCLC) cell line A549 and its cisplatin-resistant sub-line A549rCDDP2000 with
regard to cisplatin resistance mechanisms including cellular platinum accumulation, DNA-
adduct formation, cell cycle alterations, apoptosis induction and activation of key players of
DNA damage response. In A549rCDDP2000 cells, a cisplatin-induced G2/M cell cycle arrest
was lacking and apoptosis was reduced compared to A549 cells, although equitoxic cisplatin
concentrations resulted in comparable platinum-DNA adduct levels. These differences were
accompanied by changes in the expression of proteins involved in DNA damage response. In
A549 cells, cisplatin exposure led to a significantly higher expression of genes coding for pro-
teins mediating G2/M arrest and apoptosis (mouse double minute 2 homolog (MDM2), xero-
derma pigmentosum complementation group C (XPC), stress inducible protein (SIP) and
p21) compared to resistant cells. This was underlined by significantly higher protein levels of
phosphorylated Ataxia telangiectasia mutated (pAtm) and p53 in A549 cells compared to
their respective untreated control. The results were compiled in a preliminary model of resis-
tance-associated signaling alterations. In conclusion, these findings suggest that acquired
resistance of NSCLC cells against cisplatin is the consequence of altered signaling leading to
reduced G2/M cell cycle arrest and apoptosis.
Introduction
Non-small cell lung cancer (NSCLC) is associated with high incidence and mortality [1]. Cis-
platin (cis-diamminedichloroplatinum (II)) is one of the common constituents of first-line
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treatment after surgery [2]. The absolute effect of cisplatin chemotherapy after five years was
shown to be a decrease of lung cancer associated death by 6.9% compared to an untreated con-
trol group [3]. The precise antineoplastic mechanism of cisplatin remains not completely
understood [4]. Cisplatin cytotoxicity has been suggested to be predominantly mediated by
nuclear DNA binding, mainly via intrastrand DNA crosslinks leading to cell cycle arrest and
subsequent apoptosis [5]. However, this view may be an oversimplification since only around
1% of the intracellular cisplatin binds to nuclear DNA. Cisplatin becomes intracellularly acti-
vated into an aquatic complex that reacts with numerous membrane and cytoplasmic compo-
nents, suggesting that the drug may also exert cytotoxic effects by mechanisms independent of
nuclear DNA binding [6].
The efficacy of cisplatin-based chemotherapies is limited by the occurrence of innate and
acquired drug resistance. The mechanisms underlying cisplatin resistance are complex indicat-
ing that there is no single mechanism-based strategy to overcome cisplatin resistance [4,7,8].
Galuzzi et al. classified the cisplatin resistance mechanisms into four categories: (i) pre-target
resistance, preventing the binding of cisplatin to DNA by reduced cellular accumulation or
enhanced binding to cytoplasmic components; (ii) on-target resistance, by tolerating or repair-
ing cisplatin-DNA adducts; (iii) post-target resistance, by several alterations or defects in sig-
naling pathways in response to DNA damage by cisplatin; and (iv) off-target resistance, by
mechanisms, which do not directly involve cisplatin-initiated signals but enable cells to cir-
cumvent cisplatin-induced cell death [4]. Various proteins, genes or pathways were found to
be involved in resistance against cisplatin [7,8], but any of the mechanisms was identified as
the crucial one. Therefore, a single mechanism-based strategy to overcome cisplatin resistance
will unlikely be successful. Consequently, the knowledge of extensive cytoplasmic and nuclear
interactions of cisplatin and the multifactorial nature of resistance has driven us towards a
more systematic approach, leading in the far future to a holistic model to explain the develop-
ment of cisplatin resistance in NSCLC cell. Hence, we chose a bottom-up approach to compare
cisplatin-sensitive and -resistant NSCLC cells to first outline the differences in biomolecular
actions upon cisplatin exposure and then unveil the underlying mechanisms responsible.
Materials and methods
Drugs
Cis-diamminedichloroplatinum (II) (cisplatin) was obtained from Sigma–Aldrich, Steinheim,
Germany and dissolved in 0.9% NaCl at a final concentration of 1.5 g/L. The platinum concen-
tration in the stock solution was verified by flameless atomic absorption spectroscopy (AAS).
Aliquots were stored at -20˚C and thawed immediately before use.
Cell lines
The human non-small cell lung carcinoma (NSCLC) cell line A549 was obtained from ATCC
(Manassas, VA, USA) and its cisplatin resistant sub-line A549rCDDP2000 was derived from
the Resistant Cancer Cell Line (RCCL) collection (http://www.kent.ac.uk/stms/cmp/RCCL/
RCCLabout.html). The sub-line had been established by adapting the growth of A549 cells in
the presence of increasing concentrations of cisplatin until a final concentration of 2000 ng/mL
cisplatin as described previously [9]. A549 cells were grown in IMDM (PAN-Biotech, Aiden-
bach, Germany) containing 4 mM L-glutamine, supplemented with 10% fetal calf serum, 100 I.
E./mL penicillin and 0.1 mg/mL streptomycin. The medium of the A549rCDDP2000 cells ad-
ditionally contained 2 μg/mL cisplatin. Cells were cultivated as monolayers in a humidified
atmosphere at 37˚C and 5% CO2. For all experiments, cells were allowed to attach overnight,
experienced 4 h of serum starvation and were subsequently treated with cisplatin for 24 h in
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IMDMmedium without any supplement. Prior serum starvation and the use of serum-free
medium avoided the influence of growth factors in serum on cellular signaling. It however
restricted the incubation time to 24h as longer treatment can lead to starvation effects and apo-
ptosis [10]. The cisplatin concentrations used were cell line dependent and based on the respec-
tive EC10. Both cell lines were treated with 11 μM cisplatin (EC10 of sensitive cell line). The
resistant sub-line was besides treated with 34 μM cisplatin (the respective EC10). In the follow-
ing, equimolar treatment refers to treatment of sensitive and resistant cell line with 11 μM cis-
platin and equitoxic treatment refers to treatment of sensitive cell line with 11 μM cisplatin and
resistant cell line with 34 μM cisplatin.
Cisplatin cytotoxicity
MTT assays were performed to determine cisplatin cytotoxicity via cancer cell viability in
response to cisplatin. Cisplatin concentrations that resulted in 90% cell viability relative to
untreated control (EC10) were determined. The assay was performed as previously described
[11] with slight modification. Briefly, 8000 cells were seeded in a 96-well microtiter plate and
kept at 37˚C and 5% CO2 overnight. After 4 h of serum starvation, cells were treated with differ-
ent concentrations of cisplatin in growth medium without any supplements for 24 h. Following
incubation, cells were treated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT, Sigma–Aldrich, Steinheim, Germany) solution [5 mg/mL dissolved in phosphate-
buffered saline (PBS)] for 1 h. After dissolving the formazan crystals in DMSO, absorbance of
the converted dye was measured at 595 nm with background subtraction at 690 nm using the
Multiwell-Reader Multiskan EX1 (Thermo Fisher Scientific, Waltham, MA, USA). EC50 and
EC10 values (drug concentrations that reduce cell viability by 50% or 10%, respectively) were
calculated using the software PrismTM (GraphPad Software, La Jolla, CA, USA).
Cellular platinum accumulation
The cellular platinum accumulation was measured to evaluate differences in platinum uptake
in the cell lines, which contributes to resistance development. 2.5 × 105 sensitive cells and
5 × 105 of the resistant variant per well were seeded into 6-well plates and kept at 37˚C and 5%
CO2 overnight. After 4 h of serum starvation and treatment with cisplatin for 24 h, cells were
washed with ice-cold PBS, trypsinized and centrifuged for 4 minutes at 1500 x g. After lysing
the cell pellet in 50 μL concentrated HNO3 at 80˚C for 1 h, total platinum was measured by fla-
meless atomic absorption spectrometry. The diluted sample was injected into a graphite tube
and after vaporization and atomization, platinum absorption was measured at 265.9 nm and
2700˚C. The cellular platinum content was determined in relation to cellular protein content,
which was determined by the BCA assay (BCA protein assay kit, Merck KGaA, Darmstadt,
Germany).
Cisplatin-DNA adducts
Cisplatin-DNA adducts were measured by immunoblotting. After 4 h of serum starvation and
treatment with different concentrations of cisplatin for 24 h, total DNA was isolated with the
RNeasyTM Kit (Qiagen, Venlo, Netherlands). 1 μg of DNA was dissolved in Tris/EDTA (TE)
buffer and denatured at 95˚C for 10 min. Subsequently the DNA was spotted on HybondTM
nitrocellulose membranes (GE Healthcare, Chalfont, St Giles, United Kingdom) with a slot
blot manifold (GE Healthcare, Chalfont, St Giles, United Kingdom) by a vacuum of 35 kPa
(kilo-Pascal). After denaturation with 0.4 M NaOH for 45 min on a drenched filter paper the
membranes were blocked with 5% (w/v) non- fat dry milk powder (Bio-Rad Laboratories,
Hercules, CA, USA) in TBS (tris-buffered saline) with 0.1% (v/v) Tween-20 (ฬ TBS-T, Bio-Rad
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Laboratories, Hercules, CA, USA) overnight at 4˚C. Subsequently, the membranes were incu-
bated with the antibody against cisplatin-DNA adducts (Merck Millipore, Billerica, MA,
USA), diluted 1:1000 in TBS-T with 5% (w/v) non-fat dry milk powder, for 2 h at room tem-
perature to detect 1,2-d(GG) DNA intrastrand cross links. The membranes were washed 3
times with TBS-T followed by incubation with the secondary horse radish phosphatase (HRP)
coupled antibody (1:1000, Antibodies-online.com, Aachen, Germany). Antibody complexes
were detected using the enhanced chemiluminescence (ECL) reagent (Thermo Fisher Scien-
tific, Waltham, MA, USA) and densitometric analysis was carried out using the AIDATM 4
software (Raytest, Straubenhardt, Germany).
Cell cycle
Briefly, 5 × 105 sensitive cells and 1 × 106 cells of the resistant sub-line were seeded into T25
flasks and kept at 37˚C and 5% CO2 overnight. After 4 h of serum starvation and cisplatin
treatment for 24 h, the supernatant was collected and cells were washed once with PBS, har-
vested with AccuMaxTM (GE Healthcare, Chalfont, St Giles, United Kingdom) and transferred
to the consolidated supernatants. Subsequently, cells were centrifuged for 5 min at 200 x g,
supernatant was discarded and cells were fixed with 79% ethanol for 24 h at 4˚C. After fixation
the cells were centrifuged for 5 min at 1400 x g, washed with PBS and incubated with 100 μg/
mL RNase A (Life Technologies, Carlsbad, CA, USA) for 30 min at room temperature. After
staining with 5 μL propidium iodide (0.1 mg/mL in PBS, Sigma–Aldrich, Steinheim, Ger-
many) samples were analyzed using flow cytometry (FACSCaliburTM, BD Bioscience, Franklin
Lakes, NJ, USA).
Apoptosis assay
Apoptosis was investigated using the BD Pharmingen™ FITC Annexin V Apoptosis Detection
Kit (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, 2.5 × 105 sensitive cells and 5 × 105
cells of the resistant sub-line per well were seeded into 6-well plates and kept at 37˚C and 5%
CO2 overnight. After 4 h of serum starvation and 24 h treatment, trypsinized cells in growth
medium were centrifuged for 4 min at 1500 × g. The supernatant was discarded and 500 μL
binding buffer (BD Bioscience, Franklin Lakes, NJ, USA) was added to resuspend the pellet.
5 μL propidium iodide and 5 μL Annexin V-FITC were added to 100 μL of the cells in binding
buffer. After 15 min of incubation on ice, samples were analyzed using flow cytometry (FACS-
CaliburTM, BD Bioscience, Franklin Lakes, NJ, USA).
RNA isolation, cDNA synthesis and RT-PCR
RNA was isolated using the RNeasyTM Mini Kit (Qiagen, Venlo, Netherlands) and quantified
photometrically with a NanodropTM 1000 (Thermo Fisher Scientific, Waltham, MA, USA).
Subsequent cDNA synthesis was performed for 60 min at 42˚C. Reaction mixture was com-
posed of 2 μl water (Qiagen, Venlo, Netherlands), 1.5 μl 10 x buffer (Life Technologies,
Carlsbad, CA, USA), 1.1 μl MgCl2 (25 mM; Life Technologies, Carlsbad, CA, USA), 1.5 μl
dithiothreitol (100 mM; Life Technologies, Carlsbad, CA, USA), 1.5 μl dNTP (2,5 mM; Life
Technologies, Carlsbad, CA, USA), 0.6 μl Rnasin1 (20 u/μl; Life Technologies, Carlsbad, CA,
USA), 0,3 μl oligo-dt-primer (Life Technologies, Carlsbad, CA, USA) and murine leukemia
virus reverse transcriptase (50 u/μl Life Technologies, Carlsbad, CA, USA). RT-PCR was then
performed with Probes Master Light Cycler (LC) 480 (Hoffmann La Roche, Basel, Switzer-
land). Hybridization probes and primers were purchased from TIB MOLBIOL (Berlin, Ger-
many) and the sequences of those probes and primers are presented in (Table 1).
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SDS-PAGE/Western blot
Cellular proteins were extracted using Denaturizing Cell Extraction Buffer (Life Technologies,
Carlsbad, CA, USA). Protein concentration was determined by the BCA (bicinchoninic acid)
assay (PierceTM BCA Protein Assay Kit, Life Technologies, Carlsbad, CA, USA). Whole pro-
tein extracts were separated on a 4–12% Bis-Tris polyacrylamide gel according to the method
of La¨mmli [12] using MOPS electrophoresis buffer. Proteins were transferred to a PVDF
membrane (Bio-Rad Laboratories, Hercules, CA, USA), which was blocked after protein trans-
fer with 5% (w/v) not-fat dry milk powder in TBS-T (Tween-20, 0.1% (v/v)) for 1 h at room
temperature. Subsequently, the membranes were incubated overnight at 4˚C with primary
antibodies (Table 2) and washed three times for 10 min with TBS-T, followed by incubation
with the secondary HRP-conjugated antibody (Santa Cruz Biotechnology, Dallas, TX, USA)
for 1 h at room temperature. Antibody complexes were detected using the ECL reagent
(Thermo Fisher Scientific, Waltham, MA, USA) and densitometric analysis was carried out
using AIDATM 4 Software (Raytest, Straubenhardt, Germany). Protein signals were normal-
ized to the housekeeping proteins GAPDH or ċ-actin. Experiments showed reproducibly that
ċ-actin is expressed twofold higher in sensitive cells than in the resistant cells. Because some
proteins are not detectable in untreated cells and therefore a fold of control analysis is not pos-
sible the normalization on ċ-actin had to be modified to keep the densitometric analysis of
sensitive and resistant cells comparable. Therefore those proteins were normalized to ċ-actin/
2 in sensitive cells. Representative whole western blots can be found in Supporting Informa-
tion S9–S17 Figs)
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Statistical analysis
Each experiment was at least performed in triplicate unless otherwise stated and all statistical
analyses were performed using Prism1 V6 (GraphPad Software, La Jolla, CA, USA). For cis-
platin cytotoxicity experiments, dose-effect curves were calculated by non-linear regression
based on a four-parameter logistic Hill equation. EC50 values were assumed to be log-normally
distributed. pEC50 values were computed from the turning point of the dose-effect curve for
each experiment and the mean of pEC50 of all independent experiments was calculated. For
the cisplatin accumulation and DNA-adduct formation experiments, means of each indepen-
dent experiment were calculated and compared between groups by a one-way ANOVA.
To analyze whether gene/protein expression was induced by cisplatin, the significance of a
difference between treated and untreated cells was assessed using a one-sample t-test or a one-
way ANOVA with Bonferroni’s multiple comparisons test as appropriate. When a significant
difference was observed, the extent of induction was compared between the cell lines and treat-
ment conditions using a one-way ANOVA with Bonferroni’s multiple comparisons test. Dif-
ferences were considered to be statistically significant at p-values< 0.05.
Author’s notes: mRNA and protein data in the results section are presented relative to
untreated control. The individual data points showing the values of untreated controls can be
found in Supporting Information (S1–S7 Figs and S8 Fig Data Tables).
Results
Cisplatin cytotoxicity
Cisplatin cytotoxicity was markedly reduced in the A549rCDDP2000 cells (pEC50 = -4.262 ±
0.171; mean ± SD, n = 12) compared to the A549 cell line (pEC50 = -4.522 ± 0.144; n = 11)
after 24 h treatment. Based on the sigmoidal concentration-response curves, 90% viability con-
centrations (EC10 values) were determined as 11 μM in A549 and 34 μM in A549
rCDDP2000
cells (approx. factor 3) (Fig 1).
Cellular platinum accumulation
To assess cisplatin accumulation, the intracellular platinum concentration was measured in
both cell lines (Fig 2). The intracellular platinum uptake was significantly (p< 0.01) reduced
in A549rCDDP2000 cells (0.051 μmol platinum/g protein, SEM = 0.004; n = 31) compared to
Table 2. Antibodies with their respective dilution used for SDS-PAGE.
Antibody Manufacturer Dilution
Į-Actin Santa Cruz Biotechnology 1:1000
GAPDH GeneTex 1:20000
p53-HRP Santa Cruz Biotechnology 1:200
p21 Santa Cruz Biotechnology 1:200
pAtm Santa Cruz Biotechnology 1:200
GADD45a Abnova 1:4000
MDM2 GeneTex 1:1000
SIP Santa Cruz Biotechnology 1:1000
XPC Abcam 1:1000
anti-mouse HRP Santa Cruz Biotechnology 1:2000
anti-rabbit HRP Santa Cruz Biotechnology 1:2000
anti-mouse poly-HRP Thermo Fisher Scientific 1:5000
anti-rabbit poly-HRP Thermo Fisher Scientific 1:5000
https://doi.org/10.1371/journal.pone.0181081.t002
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A549 cells (0.066 μmol platinum/g protein, SEM = 0.005; n = 33) after treatment of both cell
lines with equimolar concentrations of 11 μM cisplatin. After treating the resistant cells with
an equitoxic concentration of 34 μM, the accumulated platinum content raised to 0.158 μmol
platinum/g protein (SEM = 0.013; n = 29), which was significantly higher (p< 0.0001) than in
sensitive cells treated with the equitoxic concentration.
Cisplatin-DNA adduct formation
As mentioned above, cisplatin exerts its cytotoxicity through induction of crosslinks on DNA,
which is generally seen as the primary DNA damage by the drug. After treatment with equi-
molar concentration of cisplatin, the A549rCDDP2000 cells showed a lower level of Pt-DNA
adducts. The equitoxic treatment led to an increased adduct formation in A549rCDDP2000
cells after 4 h treatment compared to A549 cells. After 24 h treatment, resistant cells showed
Fig 1. Representative sigmoidal concentration-response curve of cisplatin in A549 and A549rCDDP2000
cells. Survival is expressed in terms of % compared to untreated cells as mean SD.
https://doi.org/10.1371/journal.pone.0181081.g001
Fig 2. Cellular platinum accumulation. Accumulation of cellular platinum (n 11) in A549 and A549rCDDP2000
cells, treated with 11 ȝM or 34 ȝM cisplatin and presented as mean SEM.
https://doi.org/10.1371/journal.pone.0181081.g002
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similar DNA-platination as after 4 h, whereas an increase in platinum-DNA adduct formation
was observed in sensitive cells over time. These data indicate that A549rCDDP2000 cells ac-
quired resistance mechanisms that reduce DNA platination, e.g. by repair mechanisms, in
comparison to A549 cells. At equitoxic concentrations, cellular platinum accumulation was
about 3-fold higher in A549rCDDP2000 cells than in A549 cells. This higher intracellular plati-
num exposure did not result in enhanced cisplatin-DNA adduct formation (Fig 3).
Cell cycle analysis
A549 cells treated with 11 μM cisplatin showed a significant decrease in G1/G0 phase compared
to that of equitoxic (34 μM) and equimolar (11 μM) cisplatin treatment in A549rCDDP2000
cells (Fig 4A). A more striking difference was observed in the G2/M-phase, where A549 cells
treated with 11 μM cisplatin showed a significant level of cell cycle arrest compared to that of
A549rCDDP2000 cells, treated with either equimolar or equitoxic concentrations (Fig 4B). Thus,
A549rCDDP2000 cells seem to have a mechanism to suppress DNA damage-induced G2/M-
arrest. The fraction of cells in the S-phase did not differ among cell lines and treatments (Fig 4C).
Apoptosis induction
After treatment with 11 μM cisplatin, apoptosis was markedly induced in A549 cells.
A549rCDDP2000 cells exhibited a statistically significant reduction in the number of apoptotic
cells in response to treatment with equimolar concentrations of cisplatin compared to A549
cells. A549rCDDP2000 cell treatment with 34 μM resulted in a tendency to increase the number
of apoptotic cells compared to 11 μM cisplatin exposure, but remained lower than the number
of apoptotic cells in sensitive cells treated with the equitoxic concentration of 11 μM (Fig 5A).
Similar results were obtained by the quantification of the number of cells in SubG1-phase
(Fig 5B).
Response of the p53 system
p53 plays a major role in DNA damage response, apoptosis and cell cycle regulation. Which
path the cell enters is mainly dependent on which target genes of p53 are affected. p53 can be
activated in a number of different ways like phosphorylation and acetylation with specific
Fig 3. Cisplatin-DNA adduct formation. Content of DNA adducts (n = 3) in A549 and A549rCDDP2000 cells,
treated with 11 ȝM or 34 ȝM cisplatin for 4 h and 24 h. Results are related to A549 cells treated 4 h with 11 ȝM
cisplatin and presented as mean  SEM.
https://doi.org/10.1371/journal.pone.0181081.g003
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complex patterns of modifications assumed to trigger downstream effects [13]. Here we
focused on investigating important key players of the downstream signaling of p53 at the
mRNA and protein level in order to determine differences in genes and proteins affected by
p53 signaling in response to cisplatin treatment between A549 and A549rCDDP2000 cells. As
expected because of a minor role of changes in p53 transcription and mainly regulation on
protein level [14], p53 was not regulated at the mRNA level (Fig 6A) but showed a significantly
Fig 4. Cell cycle distribution in A549 and A549rCDDP2000 cells. Cell fraction of the flow cytometric cell
cycle analysis is presented in % of total cell population in a) G1/G0-phase, b) G2/M-phase and c) S-phase in
A549 and A549rCDDP2000 cells as untreated controls or after treatment with 11 ȝM or 34 ȝM cisplatin
presented as mean  SEM.
https://doi.org/10.1371/journal.pone.0181081.g004
Cisplatin resistance and cisplatin induced G2/M cell cycle arrest
PLOS ONE | https://doi.org/10.1371/journal.pone.0181081 July 26, 2017 9 / 26
(p< 0.01) higher baseline level in resistant cells compared to sensitive ones. There was a signif-
icant accumulation of the protein in fold change in cisplatin-treated sensitive cells compared
to resistant ones treated with 11 μM cisplatin (p< 0.01) or with 34 μM cisplatin (p< 0.001)
(Fig 6B and 6C). Absolut data revealed that only treatment in sensitive cells resulted in a sig-
nificant increase in protein accumulation. Equitoxic cisplatin treatment induced a similar
increase of p53 protein expression in A549 and A549rCDDP2000 cells (S1 Fig).
Upstream of p53, the activated DNA damage recognition protein Ataxia Telangiectasia
mutated (Atm) protein showed a higher increase in relative protein level in sensitive cells com-
pared to A549rCDDP2000 cells (Fig 7A and 7B). This difference in increase of pATM was not
significant. However, in sensitive cells the increase in pATM expression was significant com-
pared to control (p< 0.05) after treatment with 11 μM cisplatin whereas it was not significant
in resistant cells (S2 Fig).
Mouse double minute 2 homolog (MDM2) protein, a p53 target and endogenous p53
antagonist was significantly up-regulated on mRNA level (p< 0.05) after 24 h treatment with
equitoxic cisplatin concentrations in both cell lines (S3 Fig). mRNA levels were comparable in
sensitive and resistant cells. The level of induction in fold change compared to control however
showed significantly higher levels in sensitive cells compared to equimolar (p< 0.001) and
equitoxic (p< 0.001) treatment in resistant cells (Fig 8A). No significant changes in MDM2
protein expression were observed in both cell lines after cisplatin treatment (Fig 8B and 8C).
Fig 5. Apoptosis induction in A549 cells. A549rCDDP2000 cells. Apoptosis analysis with a) FITC Annexin
(n 3) and b) cell count in SubG1-phase (n = 3) presented as fold change related to respective untreated
controls in A549 and A549rCDDP2000 cells as mean  SEM.
https://doi.org/10.1371/journal.pone.0181081.g005
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Downstream of p53, p21 plays a central role in cell cycle control, regulating both, G1/S and
G2/M cell cycle checkpoints. Therefore, this protein needs to be investigated to understand dif-
ferences between cisplatin-sensitive and resistant cells with regards to cell cycle arrest. The
mRNA of p21, a protein involved in regulation of the cell cycle, was significantly higher in fold
change after 11 μM treatment in sensitive cells (p< 0.01) and after 34 μM treatment in resistant
cells (p< 0.05) compared to 11 μM treatment in resistant cells (Fig 9A). It was significantly
Fig 6. p53 mRNA and protein analysis. Analysis of p53 in a) RT-PCR (n = 3) and b) Western Blot (n = 3) as
fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as mean  SEM with c)
one representative western blot showing A549 untreated, A549 treated with 11 ȝM cisplatin, A549rCDDP2000
untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000 treated with 34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g006
Cisplatin resistance and cisplatin induced G2/M cell cycle arrest
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(p< 0.05) up-regulated on mRNA level upon all treatment conditions and in both cell lines (S4
Fig). On protein level no significant changes were observed (Fig 9B and 9C).
Relative mRNA levels of SIP, a stress-induced protein and another upstream activator
(cofactor) of p53, were significantly (p< 0.05) increased in sensitive cells after treatment with
cisplatin compared to resistant cells (Fig 10A). In A549rCDDP2000 cells, SIP expression was
not induced by cisplatin treatment in contrast to a significant increase in sensitive cells (S5
Fig). These results were not transferred to the protein level, where no regulation of protein
expression was seen (Fig 10B and 10C). However, basal levels of SIP were significantly higher
in the resistant cell line (S5 Fig).
Xeroderma pigmentosum, complementation group C (XPC) mRNA, which encodes a
member of the nucleotide excision repair system and is a downstream effector of p53, was sig-
nificantly up-regulated in fold change of control in sensitive cells after cisplatin treatment (Fig
11A). The induction of XPC mRNA expression was significantly stronger in sensitive cells
than in resistant cells, when treated with equimolar (p< 0.01) and equitoxic (p< 0.05) con-
centrations (S6 Fig). On protein level, XPC showed no significant changes after treatment with
cisplatin (Fig 11B and 11C).
Growth arrest and DNA-damage-inducible protein GADD45 alpha (GADD45a), which in
general is a downstream effector of p53 with impact on checkpoint kinases and an inducer of
cell cycle arrest, showed significantly different expression upon treatment with 11 μM cisplatin
in A549 cells compared to A549rCDDP2000 cells treated with equimolar concentration (Fig
Fig 7. pATM protein analysis. Western Blot Analysis of pAtm (n = 3) a) as fold change relative to untreated
control normalized to the housekeeper Į-actin in A549 and A549rCDDP2000 cells, presented as mean  SEM
with b) one representative western blot showing A549 untreated, A549 treated with 11 ȝM cisplatin,
A549rCDDP2000 untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000 treated with
34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g007
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12A). On the protein level, however no significant differences between treated and untreated
cells were observed (Fig 12B and 12C).
Proposed model of resistance-associated signaling alterations
Based on the results described above, a preliminary model reflecting the changes in signaling
after treatment with cisplatin in A549 and in A549rCDDP2000 cells could be constructed (Fig
Fig 8. MDM2 mRNA and protein analysis. Analysis of MDM2 in a) RT-PCR (n = 3) and b) Western Blot
(n = 3) as fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as
mean  SEM with c) one representative western blot showing A549 untreated, A549 treated with 11 ȝM
cisplatin, A549rCDDP2000 untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000
treated with 34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g008
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13). The model includes relevant genes, which are activated by cisplatin-induced DNA dam-
age. The changes associated to cisplatin treatment were compiled to explain the observed dif-
ferences in cell cycle analysis, DNA-platination and cellular cisplatin accumulation. Based on
the data from mRNA analysis, the resulting changes are indicated with red arrows. The green
arrows indicate protein up-regulation. These specific alterations lead to inhibition of cell cycle
arrest and apoptosis in A549 cells after cisplatin treatment in contrast to A549rCDDP2000 cells.
Fig 9. p21 mRNA and protein analysis. Analysis of p21 in a) RT-PCR (n = 3) and b) Western Blot (n = 3) as
fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as mean  SEM with c)
one representative western blot showing A549 untreated, A549 treated with 11 ȝM cisplatin, A549rCDDP2000
untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000 treated with 34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g009
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Discussion
We intended to elucidate molecular key events shading more light on the potential mechanis-
tic background of the cellular development of cisplatin resistance. Cisplatin treatment leads to
cisplatin-DNA adducts and DNA crosslinks. Major cellular responders to Pt-DNA adduct for-
mation are pATM and p53. We therefore focused our investigation on genes and proteins
which are potential effectors of these proteins and also assumed to be involved in cell cycle and
Fig 10. SIP mRNA and protein analysis. Analysis of SIP in a) RT-PCR (n = 3) and b) Western Blot (n = 3) as
fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as mean  SEM with c)
one representative western blot showing A549 untreated, A549 treated with 11 ȝM cisplatin, A549rCDDP2000
untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000 treated with 34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g010
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apoptosis control. MDM2 was considered of importance due to its major activity in p53 homo-
eostasis and SIP for its kinase activity on p53. p21 is an effector of p53 and a major cell cycle
checkpoint control protein [15]. XPC was in our interest as it is involved in DNA repair but
mainly also because it has been suggested to predict treatment outcome in patients with
NSCLC [16,17].
Fig 11. XPC mRNA and protein analysis. Analysis of XPC in a) RT-PCR (n = 3) and b) Western Blot (n = 3) as
fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as mean SEM with c)
one representative western blot showing A549 untreated, A549 treated with 11 ȝM cisplatin, A549rCDDP2000
untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000 treated with 34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g011
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Cell system
To elucidate the molecular mechanisms underlying acquired cisplatin resistance, we investi-
gated the NSCLC cell line A549 and its cisplatin-resistant sub-line A549rCDDP2000. The resis-
tant cells displayed a twofold higher EC50 value, lower apoptosis level, as well as alterations in
intracellular platinum accumulation and DNA platination. The results displayed here are
Fig 12. GADD45a mRNA and protein analysis. Analysis of GADD45a in a) RT-PCR (n = 3) and b) Western
Blot (n = 3) as fold change relative to untreated control in A549 and A549rCDDP2000 cells, presented as
mean  SEM with c) one representative western blot showing A549 untreated, A549 treated with 11 ȝM
cisplatin, A549rCDDP2000 untreated, A549rCDDP2000 treated with 11 ȝM cisplatin and A549rCDDP2000
treated with 34 ȝM cisplatin.
https://doi.org/10.1371/journal.pone.0181081.g012
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consistent with the two-fold lower sensitivity of resistant tumor cells to cisplatin in clinical
studies for ovarian cancer [18] and the resistance in A549 cells measured by Yang et al. [19].
The EC10 concentrations used in the experiments were precautionary to prevent effects
superimposing resistance mechanisms. They were comparable to the clinically attainable con-
centrations [20,21]. To compensate the effects of altered influx or efflux of cisplatin in resistant
cells, equitoxic concentrations were studied showing similar Pt-DNA adduct formation but
differences in drug accumulation. We previously demonstrated in other cell lines [22] that
reduced cisplatin accumulation may be one source of chemoresistance, which needs to be
interpreted in relation to DNA platination. At equimolar concentrations, platinum-DNA
adduct formation was not significantly lower in A549rCDDP2000 cells after 4 h treatment com-
pared to sensitive cells and increased over time in A549 cells only. Equitoxic concentrations
led to a subproportional increase of DNA-adduct levels in resistant cells compared to the intra-
cellular platinum accumulation. After 24 h treatment with equitoxic concentrations, DNA
adduct levels were similar in A549 and A549rCDDP2000 cells suggesting that resistant cells
exhibit a higher DNA-repair capacity than sensitive cells, as intracellular platinum accumula-
tion was significantly higher in resistant cells. Other explanations for similar DNA platination
levels despite higher cellular platinum accumulation in A549rCDDP2000 at equitoxic concen-
trations are increased sequestration in vesicles and an increased drug inactivation compared to
the sensitive cells. Glutathione or for instance glutathione-like enzymes are known to act as
detoxification agents for cisplatin [23–28].
DNA damage and repair
Although equitoxic cisplatin concentrations resulted in similar amount of Pt-DNA adducts in
sensitive and resistant cells, the cellular response showed significant differences. Apoptosis was
Fig 13. Signalling model for reduction of G2/M arrest in A549rCDDP2000 cells. Preliminary signaling model to explain the lack of a
G2/M arrest in resistant cells indicating significant protein changes after treatment comparing a) A549 and b) A549rCDDP2000 cells
based on mRNA data (red arrows) or protein data (green arrows).
https://doi.org/10.1371/journal.pone.0181081.g013
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only induced in sensitive cells pointing to an altered DNA-damage response in resistant
cells. It was previously shown that resistant NSCLC cells have a higher repair capacity [29,30].
The impact of this phenomenon leading to resistance was documented in several studies
[26,31,32]. This is in agreement with our results concerning phosphorylation of ATM, which
is responsible for the recognition of DNA double-strand breaks, finally leading to a G2/M
arrest in sensitive cells. As expected from literature, this protein shows nearly no activity in
untreated control cells. Bakkenist et al. investigated the activation of ATM and reported that
basal, dimerized ATM is inactive. While total ATM was constant, pATM level rose after DNA
damage by radiation. Only pATM after monomerization was capable of activating other pro-
teins [33].
These cellular events further lead to activation of SIP which is a cofactor of p53. SIP is capa-
ble of modulating p53 activity and leads to the expression of antiproliferative and proapoptotic
target genes of p53, like p21 [34,35]. This signaling pathway is activated after several different
stress inducers in tumor cells [34,36,37]. Activation of SIP by cisplatin promoting cell death
was also shown in other cell lines [38]. In line with this work SIP is activated after treatment
with cisplatin on mRNA level, but only in sensitive cells.
Furthermore, DNA damage tolerance may contribute to cisplatin resistance of A549rCDDP2000
cells. Cisplatin treatment significantly increased mRNA level of XPC, a protein downstream of
p53 and crucial for DNA damage recognition, in sensitive cells. This suggests higher activation
of the global genome repair pathway and therefore a lower tolerance to cisplatin-DNA adducts
in A549. Beside its role in DNA damage recognition, XPC plays a major role in altering cell
cycle after treatment with cisplatin. In XPC-deficient cell lines, the p53 pathway is altered and
cell cycle arrest, DNA repair and apoptosis are attenuated [39]. XPC-deficient transgenic mice
are highly predisposed to several types of cancer [40] and XPC/GADD45a knockout in mice
leads to development of lung tumors [41]. XPC expression is also reduced in the tumor tissue of
resistant patients compared to normal lung tissue [42]. Additionally, reduced XPCmRNA is
suggested to predict a poor outcome for patients with NSCLC [16]. Weaver et al. showed that
XPC correlates with chemoresistance in NSCLC [17]. GADD45a, also enhancing NER [43], was
induced in sensitive cells after treatment in contrast to the resistant cells were no significant up-
regulation was found. This may support the hypothesis that NER response is reduced in resis-
tant cells. Overall, it can be seen that sensitive cells show stronger reactions in mRNA expres-
sion than resistant cells. They again seem to be more robust.
Cell cycle alterations
Ataxia telangiectasia fibroblasts lack G1 and G2 phase checkpoint functions indicating that
activation of ATM to pATM is crucial for cell cycle control [44]. This is in agreement with
reduced pATM and G2/M arrest in resistant vs. sensitive cells.
GADD45a is involved in cell cycle regulation and responsible for a G2/M arrest to enhance
DNA repair [45]. GADD45a mRNA expression was increased in HDFa cells after genistein
treatment corresponding to cell cycle arrest [46]. GADD45a may contribute to the G2/M-
phase cell cycle arrest in A549 cells in response to treatment with cisplatin. Fold change of
GADD45a mRNA was significantly different in A549rCDDP2000 cells treated with 11 μM cis-
platin compared to sensitive cells after treatment. This, however, did not translate into a signif-
icant difference in GADD45a protein levels at the time point studied. Reduced expression of
GADD45a has been associated with poor survival in esophageal cancer patients [47]. The cell
cycle alterations are in agreement with previously published work [48], showing that tumor
initiating cells are prone to less G2/M-arrest after DNA-damaging treatment. Horibe et al.
showed that cisplatin resistance is linked to loss of G2/M arrest in cisplatin-resistant cells [49].
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The p53 target gene product p21 that induces cell cycle arrest in G2/M-phase was up-regulated
in sensitive and resistant cells after treatment with cisplatin. Comparing the fold change to
control, sensitive and resistant cells treated with equitoxic concentrations resulted in a signifi-
cantly higher expression of p21 than in resistant cells treated with 11 μM cisplatin. This sug-
gests a p53-mediated cell cycle arrest in sensitive cells that is inactive at the 11 μM in cisplatin-
resistant cells. Activation of this mechanism needs much higher doses in resistant cells. We
assume that this adaptation to cisplatin treatment is part of the mechanism of resistance in
A549rCDDP2000 cells.
MDM2 ubiquitinates p53 and regulates its activity and degradation in an autoregulatory
feedback loop. MDM2 was significantly activated at the mRNA level in cisplatin-treated cells
at equitoxic concentrations. The extent of activation in A549 cells was significantly higher
compared to A549rCDDP2000 cells. On protein level, no significant differences could be
observed. One result of ubiquitination by MDM2 is destabilization of p53, diminishing the res-
ervoir of p53 which could be easily and quickly activated if needed. This consecutive existing
balance between MDM2 and ubiquitinated p53 would be disturbed if MDM2 protein levels
are altered rapidly with high amplitudes, e.g. massive expression in short time. In consequence,
a significant reduction of MDM2 would lead to an over-imposing activity of p53, which is
physiologically unfavorable in resistant tumor cells. To avoid this, only moderate changes take
place in this equilibrium. As MDM2 is also a downstream transcriptional target of p53 [50],
p53 activation may be altered in resistant cells. In the future, we shall have a closer look at the
activation status of p53 after treatment with cisplatin, as this may be one key difference in p53
regulation.
Starting point for a systems approach
Based on the results presented above we have developed a signaling model (Fig 13), which dis-
plays possible connections between the key players of cellular response to cisplatin exposure.
This model reveals some mechanisms accounting for a different reaction of the sensitive and
resistant NSCLC cells to the treatment. It provides an overview of the possible roles of several
cellular proteins; however, it represents only a small part of the whole picture inside the cell.
Results frommRNA level could not necessarily be transferred to the protein level. This could be
a matter of the time point of measurement. pAtm and p53 are already activated on protein level
in sensitive cells, introducing the G2/M arrest. mRNA activation takes place at an earlier stage.
p53 is now already capable of acting as a transcription factor to activate the other proteins in the
signaling model. These are consequently activated on mRNA level but possibly not yet on pro-
tein level. A weak correlation between mRNA and protein expression has been reported earlier.
Possible mechanisms accounting for the lack of correlation include: (1) post-transcriptional fac-
tors, (2) post-translational parameters, as well as (3) noise and experimental error. It appears
difficult to assess whether translation efficiency or protein half-life most prominently impacts
the correlation between mRNA and protein abundance [51]. An analysis in a space- and time-
dependent manner should be applied in the future and may help to resolve this discrepancy.
We assume that there may not be one key driver for resistance development. Loss of activa-
tion of pATM and p53 seems to be a major step to tolerance against cisplatin in these cells
which, however, seems not surprising given the DNA-adduct formation of cisplatin. There
may be more than one or two major key regulators for activation of these two proteins. More-
over, transcription of the downstream effectors as shown for p21 is not exclusively regulated
by p53. It seems to be a complex network of different protein interactions that lead to or omit
a cellular response to cisplatin treatment. The model presented here is thus not comprehensive
and can be extended by further players. Nevertheless, it serves as a good starting point for a
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systems pharmacology approach aiming at getting a full picture of protein interactions in the
intracellular signaling network.
Conclusion
A549 and A549rCDDP2000 cells differ in their signaling response to cisplatin treatment. p53
and pATM are significantly induced only in sensitive cells on protein level. MDM2, XPC, SIP,
p21, and GADD45a are differently induced on mRNA level in resistant cells compared to sen-
sitive ones, where these key players of the downstream signaling pathways lead to G2/M arrest.
In the future, knock-out experiments should reveal connections between genes and proteins
displayed in the preliminary model. However, as this model most probably only reflects a
small part of the network, identification of more key players is needed before employing
knock-out experiments. The proposed model of resistance-associated signaling alterations
serves as a starting point for a systems pharmacology approach.
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S1 Fig. Analysis of p53. Analysis of p53 in a) RT-PCR (n = 3) as individual data points pre-
sented as mean ± SEM and b) Western Blot (n = 3) as integrated signal intensity normalized to
the housekeeper ċ-actin in A549 and A549rCDDP2000 cells, presented as mean ± SEM.
(TIF)
S2 Fig. Analysis of pAtm.Western Blot Analysis of pAtm (n = 3) a) as integrated signal inten-
sity normalized to the housekeeper ċ-actin in A549 and A549rCDDP2000 cells, presented as
mean ± SEM.
(TIF)
S3 Fig. Analysis of MDM2. Analysis of MDM2 in a) RT-PCR (n = 3) as individual data points
presented as mean ± SEM and b) Western Blot (n = 3) as integrated signal intensity normal-
ized to the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as
mean ± SEM.
(TIF)
S4 Fig. Analysis of p21. Analysis of p21 in a) RT-PCR (n = 3) as individual data points pre-
sented as mean ± SEM and b) Western Blot (n = 3) as integrated signal intensity normalized to
the housekeeper ċ-actin in A549 and A549rCDDP2000 cells, presented as mean ± SEM.
(TIF)
S5 Fig. Analysis of SIP. Analysis of SIP in a) RT-PCR (n = 3) as individual data points pre-
sented as mean ± SEM and b) Western Blot (n = 3) as integrated signal intensity normalized to
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM.
(TIF)
S6 Fig. Analysis of XPC. Analysis of XPC in a) RT-PCR (n = 3) as individual data points pre-
sented as mean ± SEM and b) Western Blot (n = 3) as integrated signal intensity normalized to
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM.
(TIF)
S7 Fig. Analysis of GADD45a. Analysis of GADD45a in a) RT-PCR (n = 3) as individual data
points presented as mean ± SEM and b)Western Blot (n = 3) as integrated signal intensity nor-
malized to the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as
mean ± SEM.
(TIF)
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S8 Fig. Tables with individual data values. Tables with individual data values analysed for
preparation of all figures in this manuscript.
(DOCX)
S9 Fig. Western Blot of ċ-Actin for p53 pATM and p21 normalization.Western Blot of ċ-
Actin in A549 and A549rCDDP2000 cells. Lanes 1, 6, 11,: A549 untreated; lanes 2, 7, 12, A549
cells treated with 11 μM cisplatin; lanes 3, 8, 13, A549rCDDP2000 untreated; lanes 4, 9, 14,
A549rCDDP2000 treated with 11 μM cisplatin; lanes 5, 10, 15, A549rCDDP2000 treated with
34 μM cisplatin.
(TIF)
S10 Fig. Western blot p53.Western Blot of p53 in A549 and A549rCDDP2000 cells. Lanes 1, 6,
11,: A549 untreated; lanes 2, 7, 12, A549 cells treated with 11 μM cisplatin; lanes 3, 8, 13,
A549rCDDP2000 untreated; lanes 4, 9, 14, A549rCDDP2000 treated with 11 μM cisplatin; lanes
5, 10, 15, A549rCDDP2000 treated with 34 μM cisplatin.
(TIF)
S11 Fig. Western blot pATM.Western Blot of pATM in A549 and A549rCDDP2000 cells.
Lanes 1, 6, 11,: A549 untreated; lanes 2, 7, 12, A549 cells treated with 11 μM cisplatin; lanes 3,
8, 13, A549rCDDP2000 untreated; lanes 4, 9, 14, A549rCDDP2000 treated with 11 μM cisplatin;
lanes 5, 10, 15, A549rCDDP2000 treated with 34 μM cisplatin.
(TIF)
S12 Fig. Western blot MDM2.Western Blot of MDM2 in A549 (caption in black letters) and
A549rCDDP2000 (caption in red letters) cells showing lanes of A549 untreated (caption ctrl),
A549 treated with 11 μM cisplatin (caption 11), A549rCDDP2000 untreated (caption ctrl),
A549rCDDP2000 treated with 11 μM cisplatin (caption 11) and A549rCDDP2000 treated with
34 μM cisplatin (caption 34). Bands of MDM2 and GAPDH are labelled accordingly.
(TIF)
S13 Fig. Western blot p21.Western Blot of p21 in A549 and A549rCDDP2000 cells. Lanes 1, 6,
11,: A549 untreated; lanes 2, 7, 12, A549 cells treated with 11 μM cisplatin; lanes 3, 8, 13,
A549rCDDP2000 untreated; lanes 4, 9, 14, A549rCDDP2000 treated with 11 μM cisplatin; lanes
5, 10, 15, A549rCDDP2000 treated with 34 μM cisplatin.
(TIF)
S14 Fig. Western blot SIP.Western Blot of SIP in A549 (caption in black letters) and
A549rCDDP2000 (caption in red letters) cells showing lanes of A549 untreated (caption ctrl),
A549 treated with 11 μM cisplatin (caption 11), A549rCDDP2000 untreated (caption ctrl),
A549rCDDP2000 treated with 11 μM cisplatin (caption 11) and A549rCDDP2000 treated with
34 μM cisplatin (caption 34). Bands of SIP and GAPDH are labelled accordingly.
(TIF)
S15 Fig. Western blot XPC.Western Blot of XPC in A549 (caption in black letters) and
A549rCDDP2000 (caption in red letters) cells showing lanes of A549 untreated (caption ctrl),
A549 treated with 11 μM cisplatin (caption 11), A549rCDDP2000 untreated (caption ctrl),
A549rCDDP2000 treated with 11 μM cisplatin (caption 11) and A549rCDDP2000 treated with
34 μM cisplatin (caption 34). Bands of XPC and GAPDH are labelled accordingly.
(TIF)
S16 Fig. Western blot GADD45a.Western Blot of GADD45a in A549 (caption in black let-
ters) and A549rCDDP2000 (caption in red letters) cells showing lanes of A549 untreated (cap-
tion ctrl), A549 treated with 11 μM cisplatin (caption 11), A549rCDDP2000 untreated
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(caption ctrl), A549rCDDP2000 treated with 11 μM cisplatin (caption 11) and
A549rCDDP2000 treated with 34 μM cisplatin (caption 34).
(TIF)
S17 Fig. Western blot of GAPDH for GADD45a normalization.Western Blot of GAPDH
for GADD45a normalization in A549 (caption in black letters) and A549rCDDP2000 (caption
in red letters) cells showing lanes of A549 untreated (caption ctrl), A549 treated with 11 μM
cisplatin (caption 11), A549rCDDP2000 untreated (caption ctrl), A549rCDDP2000 treated with
11 μM cisplatin (caption 11) and A549rCDDP2000 treated with 34 μM cisplatin (caption 34).
(TIF)
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